publications-banner

Information about pipeline products

PublicationView

Pexidartinib
Other/Multi-Tumor
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
Lee JH, Chen TWW, Hsu CH, et al.
Invest New Drugs. 2020;38(1):99-110.
Valemetostat
Hematology
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
Izutsu K, Makita S, Nosaka K, et al.
Blood. 2023;141(10):1159-1168.
T-DXd
Breast Cancer
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Garrido C, Manoogian M, Ghambire D, et al.
Virchows Arch. 2023. doi: 10.1007/s00428-023-03671-x. Online ahead of print.
T-DXd
Breast Cancer
Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study
Modi S, Park H, Murthy RK, et al.
J Clin Oncol. 2020;38(17):1887-1896.
Dato-DXd
Lung Cancer Other/Multi-Tumor
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development
Lu Y, Liang S, Hong Y, et al.
CPT Pharmacometrics Syst Pharmacol. 2023. doi: 10.1002/psp4.13058. Online ahead of print.
HER3-DXd
Other/Multi-Tumor
Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima Y, Sudo K, Yoshida H, et al.
Kojima et al. Cancer Cell International (2023) 23:18 https://doi.org/10.1186/s12935-022-02844-z
Quizartinib
Hematology
Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QUANTUM-R trial
Ganguly S, Cortes JE, Kramer A, et al.
Transplant Cell Ther. 2021;27(2):153-162.
T-DXd
Breast Cancer
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
Paulissen JHJ, Seddik AH, Dunton KJ, et al.
Eur J Health Econ. 2023. doi: 10.1007/s10198-023-01617-3. Online ahead of print.
HER3-DXd
Lung Cancer
Current and emerging treatment options for patients with metastatic EGFR-mutated non-small cell lung cancer after progression on osimertinib and platinum-based chemotherapy: A podcast discussion
Patel S, Patel JD.
Adv Ther. 2023;40(12):5579-5590.
Pexidartinib
Other/Multi-Tumor
Dosing recommendation based on the effects of different meal types on pexidartinib pharmacokinetics in healthy subjects: Implementation of model-informed drug development strategy
Zahir H, Yin O, Hsu C, et al.
Clin Pharmacol Drug Dev. 2023;12(5):475-483.
Páginas: 1  2  3  4  5  6  7  

footer